Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$108.0 million.

  • Agios Pharmaceuticals' Profit After Tax fell 1193.08% to -$108.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$412.8 million, marking a year-over-year decrease of 16126.85%. This contributed to the annual value of -$412.8 million for FY2025, which is 16126.85% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Profit After Tax stood at -$108.0 million for Q4 2025, which was down 1193.08% from -$103.4 million recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Profit After Tax peaked at $1.9 billion during Q1 2021, and registered a low of -$112.0 million during Q2 2025.
  • For the 5-year period, Agios Pharmaceuticals' Profit After Tax averaged around $64.1 million, with its median value being -$90.3 million (2023).
  • Its Profit After Tax has fluctuated over the past 5 years, first skyrocketed by 475601.4% in 2021, then crashed by 36266.22% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Profit After Tax (Quarter) stood at -$94.6 million in 2021, then surged by 138.6% to $36.5 million in 2022, then tumbled by 362.66% to -$95.9 million in 2023, then dropped by 0.61% to -$96.5 million in 2024, then decreased by 11.93% to -$108.0 million in 2025.
  • Its last three reported values are -$108.0 million in Q4 2025, -$103.4 million for Q3 2025, and -$112.0 million during Q2 2025.